Výsledky vyhledávání - "Christopher J. Maddage"

Supplemental Figure S7 from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity

Autor: Earl F. Albone, Luigi Grasso, Toshimitsu Uenaka, Frank Fang, Keiji Furuuchi, Megan Kuc, Danielle Fernando, Shawn Fernando, Katherine A. Rybinski, Christopher J. Maddage, Arielle C. Verdi, Andrew Z. Milinichik, Utpal Majumder, Keigo Tanaka, Jing Li, Xin Cheng

FRA expression on regrown MORAb-202-treated LXFA-737 non-small cell lung carcinoma PDX tumors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c57ac17a877cd93ce6e5a45934e3e588
https://doi.org/10.1158/1535-7163.22504738

Zobrazit plný text záznamu

Data from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity

Microtubule-targeting agents (MTA) have been investigated for many years as payloads for antibody–drug conjugates (ADC). In many cases, these ADCs have shown limited benefits due to lack of efficacy or significant toxicity, which has spurred contin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::568f92c858fd241091aa4a5827363206
https://doi.org/10.1158/1535-7163.c.6537841.v1

Zobrazit plný text záznamu

Supplemental Figure S5 from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity

Specificity of MORAb-202 cytotoxicity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f83f03398bd9719a130f22d1e871f77
https://doi.org/10.1158/1535-7163.22504744.v1

Zobrazit plný text záznamu

Supplemental Figure S2 from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity

DAR-sensitive label-free assay method design and maximal binding determination

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e4f8c9e35950f1c372cd31b305c782
https://doi.org/10.1158/1535-7163.22504756.v1

Zobrazit plný text záznamu

Supplemental Figure S1 from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity

Eribulin compound structures and synthetic methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6278f5f216a99a548d2b0e5acb9f3365
https://doi.org/10.1158/1535-7163.22504759.v1

Zobrazit plný text záznamu

Supplemental Figure S6 from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity

Minimum effective dose of eribulin in NCI-H2110 tumor-bearing mice.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e9428a4a3e1aca4345a4defb57ff1b7
https://doi.org/10.1158/1535-7163.22504741

Zobrazit plný text záznamu

Supplemental Figure S3 from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity

Analyses of faletuzumab and amatuximab ADCs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9f950144be3df06a83a14f215b297b7
https://doi.org/10.1158/1535-7163.22504753

Zobrazit plný text záznamu

Supplemental Figure S4 from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity

Biophysical analyses of MORAb-202 large-scale conjugation.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d81c847504e71ff00cd01530d7373d37
https://doi.org/10.1158/1535-7163.22504750

Zobrazit plný text záznamu

MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity

Autor: Andrew Z. Milinichik, Toshimitsu Uenaka, Megan Kuc, Utpal Majumder, Francis G. Fang, Keigo Tanaka, Danielle Fernando, Katherine Rybinski, Christopher J Maddage, Keiji Furuuchi, Shawn Fernando, Luigi Grasso, Xin Cheng, Earl Albone, Arielle Verdi, Jing Li

Publikováno v: Molecular cancer therapeutics. 17(12)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e40f0a749390c8011f1def9b9ca84be
https://pubmed.ncbi.nlm.nih.gov/30262588

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání